#MarketingAuthorisation
LightNews LightNews
4040rec.bsky.social
#PharmaTimes #pharma #pharmaceuticals #Brensocatib #Brinsupri #noncysticfibrosisbronchiectasis #MHRA #MedicinesandHealthcareproductsRegulatoryAgency #marketingauthorisation #chroniccondition #dipeptidylpeptidase1 #inflammatoryprocess #lungs #respiratory #JulianBeach
zurl.co/LPYPc
Brensocatib becomes first licensed treatment for non‑cystic fibrosis bronchiectasis - PharmaTimes
MHRA authorises medicine for patients aged 12 and over with repeated flare‑ups
pharmatimes.com
February 26, 2026 at 10:15 AM
4040rec.bsky.social
#mentalhealth #GedeonRichter #UK #cariprazine #neuropsychiatry #marketingtransfer #Recordati #GedeonRichterUK #RecordatiPharmaceuticals #UKpromotion #MarketingAuthorisation #schizophrenia #adults #centralnervoussystem #CNS #chronicmentalhealthcondition
zurl.co/pROEi
Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes
Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati
pharmatimes.com
February 3, 2026 at 1:09 PM
4040rec.bsky.social
#ROMVIMZA #Vimseltinib #TGCTtreatment #tenosynovialgiantcelltumour #EU #symptomatictenosynovialgiantcelltumour #TGCT #marketingauthorisation #TGCTtherapy #OnoPharmaceutical #Deciphera #phase3MOTIONstudy #Secondaryendpoints #tumourresponse #stiffness #qualityoflife
pharmatimes.com/news/europea...
European Commission approves ROMVIMZA for TGCT treatment - PharmaTimes
Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU
pharmatimes.com
September 22, 2025 at 8:26 AM
4040rec.bsky.social
#vaccines #Moderna #COVID19vaccine #Spikevax #LP81variant #marketingauthorisation #updatedCOVID19vaccine #SARSCoV2variantLP81 #EuropeanMedicinesAgency #EMA #20252026vaccinationseason #eligiblepopulations #globalhealthauthorities #ModernaCOVID19vaccines
pharmatimes.com/news/moderna...
Moderna wins EU approval for updated COVID-19 vaccine - PharmaTimes
Spikevax authorised to target LP.8.1 variant ahead of 2025-2026 season
pharmatimes.com
August 13, 2025 at 8:25 AM
4040rec.bsky.social
#Accesstonewmedicines #NHSFunding #Integratedcare #NICE #ABPI #lifesciences #Marketingauthorisation #EAMS #QALYs #ICER #HST #BIT #DHSC #VPAG #VPAS #PPRS #ATMPs #HTA #formularies #clinicalpathways #ICBs #IMOC #medicaldevices #medicalappliances #wounddressings
www.kingsfund.org.uk/insight-and-...
Access To New Medicines In The English NHS | The King's Fund
Have you ever wondered how new medicines are developed, approved and priced? This explainer outlines the long journey from the discovery of a new drug to when it becomes available on the NHS.
www.kingsfund.org.uk
July 2, 2025 at 12:03 PM
4040rec.bsky.social
#ophthalmology #optics #eyehealth #Santen #Ryjunea #paediatricmyopia #childhoodmyopia #marketingauthorisation #atropineeyedrop #childhoodeyecare #managingmyopia #children #myopiaprogression #SydnexisInc #phase3starstudy #shortsightedness #severeeyeconditions
pharmatimes.com/news/europea...
EC approves Santen’s Ryjunea to slow progression of paediatric myopia - PharmaTimes
Therapy indicated for children aged 3 to 14 at treatment initiation
pharmatimes.com
June 5, 2025 at 10:12 AM
4040rec.bsky.social
#gastro #immunology #gastroenterology #mirikizumab #Omvoh #EliLilly #Crohnsdisease #Crohnsdiseasetreatment #NICE #NICEfinaldraftguidance #MHRA #marketingauthorisation #VIVID1clinicaltrial #clinicalremission #inflammatoryboweldisease #CrohnsandColitisUK
pharmatimes.com/news/nice-re...
NICE recommends mirikizumab for Crohn's disease treatment - PharmaTimes
New guidance expands treatment options for eligible patients
pharmatimes.com
June 3, 2025 at 9:47 AM
4040rec.bsky.social
#thyroideyedisease #TED #Amgen #Tepezza #Teprotumumab #Gravesophthalmopath #GravesEyeDisease #autoimmunedisorder #overactivethyroid #marketingauthorisation #MHRA #immunotherapy #insulinlikegrowthfactor1receptor #IGF1R #phase3OPTICtrial #OPTICtrial #proptosis
pharmatimes.com/news/amgens-...
Amgen’s Tepezza granted marketing authorisation in the UK - PharmaTimes
Teprotumumab approved as first targeted treatment for thyroid eye disease
pharmatimes.com
May 13, 2025 at 8:36 AM
4040rec.bsky.social
#AbbVie #Rinvoq #upadacitinib #giantcellarteritis #oralJAKinhibitor #JAKinhibitor #marketingauthorisation #Januskinaseinhibitor #SELECTGCAtrial #immunology #pharma #pharmaceuticals
zurl.co/ovP8I
AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis - PMLiVE
The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population
pmlive.com
April 16, 2025 at 7:47 AM
gmj-georgia.bsky.social
BREAKING: UK's MHRA has granted marketing authorisations to 47 new medicines in 2026, marking a significant milestone for pharmaceutical innovat…

#Drugapproval #Marketingauthorisation #MHRA #Pharmaceuticalregulation #UKmedicines

#Drugapproval #Marketingauthorisation #MHRA #Pharmaceuticalregulat…
MHRA Grants 47 New Medicine Approvals in 2026
BREAKING: UK's MHRA has granted marketing authorisations to 47 new medicines in 2026, marking a significant milestone for pharmaceutical innovat… #Drugapproval #Marketingauthorisation #MHRA #Pharmaceuticalregulation #UKmedicines
news.gmj.ge
June 2, 2026 at 6:50 PM